32 results about "Posterior subcapsular lens opacities" patented technology

Containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

The invention discloses an application of pirfenidone in the preparation of medicaments for controlling proliferative diseases after an ophthalmologic operation and eye drops thereof. According to the invention, pirfenidone is prepared into the eye drops. Experiments show that pirfenidone has good stability and good ocular tissue permeability, can inhibit HLECs migration and propagation, and has no cytotoxicity to HLECs within the action range (0-1mg / ml). With pirfenidone being within the range of 0-1%, the eye drops are continuously applied on eyes within a month with safety and with no obvious toxic and side effect. Pirfenidone can be used to delay the generation of PCO after the rabbit corneal Phaco operation, reduce HLECs propagation and minimize the shield of PCO to an optical region. In addition, there is no obvious ocular surface injury or postoperative inflammation aggravation and severe adverse reaction after PFD is applied in the rabbit corneal Phaco operation. Therefore, pirfenidone can be used to control proliferative diseases after an ophthalmologic operation, especially posterior capsule opacification generated after a cataract surgery.